SAGILITY INDIA LIMITED (SAGILITY) Fair Value & Analysis
Healthcare · IN · Market cap ₹192B
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 4 days ago
Fair value updated Aug 13, 2026, revised from ₹39.51 to ₹43.46 (+10.0%) since Aug 8, 2026. Share price +1.8% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (₹30.08 to ₹54.32) leaves room in how you read the outcome.
Price vs Fair Value (21 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
21‑month range ₹27.93 – ₹54.40 · fair‑value band ₹30.08 – ₹54.32 · the ₹42.40 price screens below the ₹43.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
SAGILITY INDIA LIMITED (SAGILITY) currently trades at ₹42.40, while our model-based Fair Value estimate is ₹43.46, implying the stock looks roughly 2.5% fairly valued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, SAGILITY INDIA LIMITED generated revenue of ₹71.9B at a net margin of 12.9%. Revenue grew 29.1% year over year. It earns a return on equity of 10.3%. Net debt stands at ₹5.4B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹30.08 (bear case) to ₹54.32 (bull case); at ₹42.40, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at 3%, SAGILITY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹74.02) versus Dividend Discount (₹0.8000). Highest evidence: Growth DCF (80).
Notify me when SAGILITY reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sagility Limited engages in the provision of business process management services to the healthcare and insurance industries in India, Jamaica, the Philippines, the United States, and Colombia.
Full company description
Sagility Limited engages in the provision of business process management services to the healthcare and insurance industries in India, Jamaica, the Philippines, the United States, and Colombia. The company offers claims cost containment and management, member and provider engagement, enrolment, benefits plan building, payment integrity and billing, credentialing, clinical and case management, provider network operation services, analytics, front and back-office, administrative support provider, and data management services. It also provides utilization and care management, and population health management, as well as revenue cycle management functions, such as financial clearance, medical coding, billing, labs and durable medical equipment support, patient access and engagement, and accounts receivable follow-up services. In addition, it provides services to pharmacy benefit managers that manage prescription drugs for members under health insurance plans. Further, it offers various platforms, including document processing engine, genAI solutions for customer and member engagement, nurse assist, revenue cycle management, provider forward, enrolment and plan automation, and contract central. The company was formerly known as Sagility India Limited and changed its name to Sagility Limited in August 2025. The company was incorporated in 2021 and is based in Bengaluru, India. Sagility Limited operates as a subsidiary of Sagility B.V.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
SAGILITY INDIA LIMITED reported revenue of ₹71.9B in FY2026 versus ₹13.9B in FY2022, a compound +51.0%/yr. Reported net income was ₹9.2B in FY2026.
Watch SAGILITY: get an alert when its fair value changes →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $58.48 | $17.18 | -71% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare SAGILITY INDIA LIMITED with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SAGILITY INDIA LIMITED (SAGILITY) overvalued or undervalued?
What is the fair value of SAGILITY?
What is the quality score of SAGILITY?
What is the revenue of SAGILITY INDIA LIMITED (SAGILITY)?
What is the net profit margin of SAGILITY?
Does SAGILITY INDIA LIMITED pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SAGILITY INDIA LIMITED and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.